The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2026 | The efficacy and safety of momelotinib in myelofibrosis with a focus on anemia outcomes
In this video, Jowan Al-Nusair, MD, Marshall University, Huntington, WV, briefly discusses the findings of a systematic review and meta-analysis evaluating the efficacy and safety of momelotinib in myelofibrosis (MF), with a focus on anemia outcomes. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
I also want to discuss my systematic review and meta-analysis that was recently published on momelotinib in myelofibrosis. Momelotinib, as you know, is an ACVR1, JAK1, and JAK2 inhibitor that basically improves anemia symptoms and splenomegaly through, or primarily through hepcidin regulation. And in our meta-analysis, we found that momelotinib not only improved anemia, but also quality of life for these patients without, you know, increase in adverse events...
I also want to discuss my systematic review and meta-analysis that was recently published on momelotinib in myelofibrosis. Momelotinib, as you know, is an ACVR1, JAK1, and JAK2 inhibitor that basically improves anemia symptoms and splenomegaly through, or primarily through hepcidin regulation. And in our meta-analysis, we found that momelotinib not only improved anemia, but also quality of life for these patients without, you know, increase in adverse events. And of course, there was a lot of, you know, heterogeneity in the control groups, which may have limited like direct efficacy comparisons and I think that this calls for larger studies to also kind of look at its safety and efficacy.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
